Prioritizing the scale-up of interventions for malaria control and elimination

BackgroundA core set of intervention and treatment options are recommended by the World Health Organization for use against falciparum malaria. These are treatment, long-lasting insecticide-treated bed nets, indoor residual spraying, and chemoprevention options. Both domestic and foreign aid funding for these tools is limited. When faced with budget restrictions, the introduction and scale-up of intervention and treatment options must be prioritized.MethodsEstimates of the cost and impact of different interventions were combined with a mathematical model of malaria transmission to estimate the most cost-effective prioritization of interventions. The incremental cost effectiveness ratio was used to select between scaling coverage of current interventions or the introduction of an additional intervention tool.ResultsPrevention, in the form of vector control, is highly cost effective and scale-up is prioritized in all scenarios. Prevention reduces malaria burden and therefore allows treatment to be implemented in a more cost-effective manner by reducing the strain on the health system. The chemoprevention measures (seasonal malaria chemoprevention and intermittent preventive treatment in infants) are additional tools that, provided sufficient funding, are implemented alongside treatment scale-up. Future tools, such as RTS,S vaccine, have impact in areas of higher transmission but were introduced later than core interventions.ConclusionsIn a programme that is budget restricted, it is essential that investment in available tools be effectively prioritized to maximize impact for a given investment. The cornerstones of malaria control: vector control and treatment, remain vital, but questions of when to scale and when to introduce other interventions must be rigorously assessed. This quantitative analysis considers the scale-up or core interventions to inform decision making in this area.

[1]  Yuming Guo,et al.  The effect of air pollution on human physiological function in China: a longitudinal study , 2015, The Lancet.

[2]  P. Winskill,et al.  Modelling the cost-effectiveness of introducing the RTS,S malaria vaccine relative to scaling up other malaria interventions in sub-Saharan Africa , 2017, BMJ Global Health.

[3]  S. C. T. P. Rts Efficacy and safety of RTS,S/AS01 malaria vaccine with or without a booster dose in infants and children in Africa: final results of a phase 3, individually randomised, controlled trial , 2015, The Lancet.

[4]  Joseph Keating,et al.  Strategic roles for behaviour change communication in a changing malaria landscape , 2014, Malaria Journal.

[5]  M. Tanner,et al.  The Cost-Effectiveness of Intermittent Preventive Treatment for Malaria in Infants in Sub-Saharan Africa , 2010, PloS one.

[6]  A. Ramsay,et al.  The need for operational research and capacity-building in support of the Global Technical Strategy for Malaria 2016–2030 , 2016, Malaria Journal.

[7]  J. Skordis-Worrall,et al.  Cost and cost effectiveness of long-lasting insecticide-treated bed nets - a model-based analysis , 2012, Cost Effectiveness and Resource Allocation.

[8]  C. Menéndez,et al.  Cost-Effectiveness of Intermittent Preventive Treatment of Malaria in Pregnancy in Southern Mozambique , 2010, PloS one.

[9]  王德伦 英语-翻译-Internet , 2000 .

[10]  Gao Qi,et al.  Global technical strategy for malaria 2016–2030 , 2015 .

[11]  A. Ghani,et al.  Costs and cost-effectiveness of malaria control interventions - a systematic review , 2011, Malaria Journal.

[12]  Samir Bhatt,et al.  Coverage and system efficiencies of insecticide-treated nets in Africa from 2000 to 2017 , 2015, eLife.

[13]  S. Bhatt,et al.  Global investment targets for malaria control and elimination between 2016 and 2030 , 2017, BMJ Global Health.

[14]  Caroline W. Kabaria,et al.  A global map of dominant malaria vectors , 2012, Parasites & Vectors.

[15]  Samir Bhatt,et al.  Quantifying the contribution of Plasmodium falciparum malaria to febrile illness amongst African children , 2017, eLife.

[16]  Peter G. Kremsner,et al.  Efficacy and safety of RTS,S/AS01 malaria vaccine with or without a booster dose in infants and children in Africa: final results of a phase 3, individually randomised, controlled trial. , 2015 .

[17]  Neil M Ferguson,et al.  Modelling the impact of vector control interventions on Anopheles gambiae population dynamics , 2011, Parasites & Vectors.

[18]  P. Walker,et al.  Estimating the most efficient allocation of interventions to achieve reductions in Plasmodium falciparum malaria burden and transmission in Africa: a modelling study. , 2016, The Lancet. Global health.

[19]  A. Ghani,et al.  Gradual acquisition of immunity to severe malaria with increasing exposure , 2015, Proceedings of the Royal Society B: Biological Sciences.

[20]  M. Aikins,et al.  Cost-effectiveness of seasonal malaria chemoprevention in upper west region of Ghana , 2016, Malaria Journal.

[21]  F. Tediosi,et al.  Costing RTS,S introduction in Burkina Faso, Ghana, Kenya, Senegal, Tanzania, and Uganda: A generalizable approach drawing on publicly available data , 2015, Vaccine.

[22]  Thomas A. Smith,et al.  Determinants of the Cost-Effectiveness of Intermittent Preventive Treatment for Malaria in Infants and Children , 2011, PloS one.

[23]  P. Gething,et al.  Population coverage of artemisinin-based combination treatment in children younger than 5 years with fever and Plasmodium falciparum infection in Africa, 2003–2015: a modelling study using data from national surveys , 2017, The Lancet. Global health.

[24]  B. Hamainza,et al.  Relative costs and effectiveness of treating uncomplicated malaria in two rural districts in Zambia: implications for nationwide scale-up of home-based management , 2011, Malaria Journal.

[25]  J. Birt,et al.  Methodologies used in cost-effectiveness models for evaluating treatments in major depressive disorder: a systematic review , 2012, Cost Effectiveness and Resource Allocation.

[26]  P. Gething,et al.  Potential for reduction of burden and local elimination of malaria by reducing Plasmodium falciparum malaria transmission: a mathematical modelling study. , 2016, The Lancet. Infectious diseases.

[27]  Hannah C. Slater,et al.  The US President's Malaria Initiative, Plasmodium falciparum transmission and mortality: A modelling study , 2017, PLoS medicine.

[28]  Katya Galactionova,et al.  Public health impact and cost-effectiveness of the RTS,S/AS01 malaria vaccine: a systematic comparison of predictions from four mathematical models , 2016, The Lancet.

[29]  T. Edejer,et al.  Disease control programme support costs: an update of WHO-CHOICE methodology, price databases and quantity assumptions , 2017, Cost Effectiveness and Resource Allocation.

[30]  Wes Hinsley,et al.  Reducing Plasmodium falciparum Malaria Transmission in Africa: A Model-Based Evaluation of Intervention Strategies , 2010, PLoS medicine.

[31]  Neil M. Ferguson,et al.  Estimates of the changing age-burden of Plasmodium falciparum malaria disease in sub-Saharan Africa , 2014, Nature Communications.